-
Feb 12, 2021 11:13 AM IST This follows the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, a Biocon statement said on Friday.
-
Feb 02, 2021 09:11 PM IST Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 385 in its research report dated January 22, 2021.
-
Feb 01, 2021 06:36 PM IST Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 470 in its research report dated January 22, 2021.
-
Jan 28, 2021 02:58 PM IST ICICI Direct recommended hold rating on Biocon with a target price of Rs 450 in its research report dated January 22, 2021.
-
Jan 25, 2021 02:55 PM IST Biocon’s revenue from the biologics business in Q3FY21 was Rs 769 Crore, a 11 percent increase year-on-year and 14 percent rise quarter-on-quarter, Biocon said in a BSE filing.
-
Jan 25, 2021 10:00 AM IST CLSA has retained sell on the stock and has cut target to Rs 240 from Rs 260 per share
-
Jan 22, 2021 06:56 PM IST Expenses rose to Rs 1,642.6 crore for the December quarter, an increase of 14.52 percent, as against Rs 1,434.3 crore in the year-ago period.
-
Jan 22, 2021 12:00 PM IST -
Jan 22, 2021 12:00 PM IST -
Jan 22, 2021 10:02 AM IST The generics business reported a 3 percent dip in the third quarter at Rs 561 crore, as against Rs 576 crore in the corresponding period last year.
-
Jan 18, 2021 07:58 PM IST Net Sales are expected to increase by 15.4 percent Y-o-Y (up 15.7 percent Q-o-Q) to Rs. 2,018.1 crore, according to ICICI Direct.
-
Jan 08, 2021 09:51 AM IST The transaction is subject to customary condition precedents and approvals. Post the completion of this transaction, Biocon Ltd will hold 89.89 percent stake in Biocon Biologics on a fully diluted basis, the company said.
-
Jan 07, 2021 05:05 PM IST The current investment has put the post-money valuation of Biocon Biologics at ~$4.17 billion, said Kiran Mazumdar-Shaw, Executive Chairperson of Biocon
-
Dec 29, 2020 12:20 PM IST Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 520 in its research report dated December 28, 2020.
-
Dec 29, 2020 09:47 AM IST The share touched its 52-week high Rs 487.70 and 52-week low Rs 235.80 on 23 December, 2020 and 19 March, 2020, respectively.
-
Dec 28, 2020 10:19 AM IST Biocon Biologics, and Mylan have been informed by the US health regulator of deferred action on the biologics licence application for a biosimilar to drug Avastin, used to treat various types of cancers, Biocon said.
-
Dec 18, 2020 03:24 PM IST Avani, daughter of SpiceJet Chairman & MD Ajay Singh, is the CEO of SpiceHealth
-
Dec 03, 2020 05:46 PM IST With a net worth of Rs 54,850 crore, HCL Technologies Chairperson Roshni Nadar Malhotra is India's richest women in 2020, according to a study by Kotak Wealth and Hurun India. Biocon Chairperson Kiran Mazumdar-Shaw is the second-richest woman on the list, with a net worth of 36,600 crore, followed by Leena Gandhi Tewari, Chairperson of USV (Rs 21,340 crore). The cumulative wealth of the 100 women on the list is Rs 2.73 lakh crore, the study said. Here are India's richest women in 2020, as per the Kotak Wealth Hurun list:
-
Dec 03, 2020 03:36 PM IST Biocon Chairperson Kiran Mazumdar-Shaw is the second-richest woman on the list, with a net worth of 36,600 crore
-
Dec 03, 2020 01:23 PM IST To attain self-reliance, Indian companies still need to harness innovation through international partnerships and collaborations, Kiran Mazumdar-Shaw has said.
-
Dec 02, 2020 09:45 AM IST Efforts to diversify will open up new opportunities for Laurus Labs and make it move towards a higher-margin trajectory
-
Nov 24, 2020 12:21 PM IST If the negotiations fructify— coming two weeks after the Goldman Sachs deal—it would mark the fourth successive investment in the Kiran Mazumdar Shaw-led Biocon unit in 2020.The last fundraise was struck at a valuation of $3.94 billion.
-
Nov 21, 2020 04:06 PM IST ZS PRIZE is open to students and professionals from the start-up, enterprise, and NGO sectors of India. Indian citizens above the age of 18 can submit their ideas or solution prototypes till December 21, 2020
-
Nov 07, 2020 04:04 PM IST As per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions
-
Oct 27, 2020 06:58 PM IST Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 400 in its research report dated October 23, 2020.